戻る Agenda
[Session 3]Cardiovascular risk assessment of antitumor drugs
Session Chair(s)
Keita Fujikawa
Head of General Medicine, Japan Medical Office, Takeda Pharmaceutical Company Limited, Japan
Yuji Kumagai, MD, PHD
Professor, Kitasato Clinical Research Center, Kitasato University Hospital, Japan
Speaker(s)
Tadahiro Shinozawa, PHD
Associate Director, Drug Safety Research Lab, Regenerative Medicine Unit, Takeda Pharmaceutical Company Limited, Japan
Safety translational research for cardio-oncology using iPS cells
Yoshito Zamami
Associate professor, Department of Clinical Pharmacology and Therapeutics,, Tokushima University Graduate School, Japan
Development of preventive treatment against anticancer drug-induced side effects using big data analysis
Hideaki Takahashi
Reviewer, Pharmacheuticals and Medical Devices Agency, Japan
Cardiovascular risk assessment of antitumor drugs